Business Description
Kezar Life Sciences Inc
NAICS : 325412
SIC : 2834
ISIN : US49372L1008
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 10.64 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | -0.19 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -1.64 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -14.4 | |||||
3-Year EPS without NRI Growth Rate | -11.4 | |||||
3-Year FCF Growth Rate | -10.9 | |||||
3-Year Book Growth Rate | -5.4 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 46.43 | |||||
9-Day RSI | 43.73 | |||||
14-Day RSI | 43.48 | |||||
6-1 Month Momentum % | -16.98 | |||||
12-1 Month Momentum % | -64.8 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 11.66 | |||||
Quick Ratio | 11.66 | |||||
Cash Ratio | 11.35 | |||||
Days Sales Outstanding | 365 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.2 | |||||
Shareholder Yield % | -7.63 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -1503.39 | |||||
Net Margin % | -1455.29 | |||||
FCF Margin % | -1192.21 | |||||
ROE % | -43.98 | |||||
ROA % | -38.65 | |||||
ROIC % | -465.72 | |||||
ROC (Joel Greenblatt) % | -805.94 | |||||
ROCE % | -40.29 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 8.5 | |||||
PB Ratio | 0.32 | |||||
Price-to-Tangible-Book | 0.32 | |||||
EV-to-EBIT | 1.25 | |||||
EV-to-EBITDA | 1.26 | |||||
EV-to-Revenue | -17.92 | |||||
EV-to-FCF | 1.5 | |||||
Price-to-Net-Current-Asset-Value | 0.34 | |||||
Price-to-Net-Cash | 0.36 | |||||
Earnings Yield (Greenblatt) % | 80 | |||||
FCF Yield % | -140.38 |